194 related articles for article (PubMed ID: 16222837)
1. Detective work: reading fine print, insurers question studies of drugs; Kaiser's veteran sleuth scours medical-journal articles and sees marketing spin; doctors fear loss of choices.
Mathews AW
Wall St J (East Ed); 2005 Aug; ():A1, A6. PubMed ID: 16222837
[No Abstract] [Full Text] [Related]
2. The formulary files. Step therapy for antidepressants saves 11.7 percent in one year.
Manag Care; 2006 Nov; 15(11):59. PubMed ID: 17168073
[No Abstract] [Full Text] [Related]
3. Perspectives. Drug formularies pose legal threat to providers.
Moskowitz DB
Faulkner Grays Med Health; 1995 Feb; 49(6):suppl 1-4. PubMed ID: 10139750
[No Abstract] [Full Text] [Related]
4. Data watch. Is this the way to manage pharmacy costs?
Bus Health; 1997 Sep; 15(9):94. PubMed ID: 10173238
[No Abstract] [Full Text] [Related]
5. As drug costs rise, health plans shift the burden.
Capitation Manag Rep; 1997 Oct; 4(10):153-8. PubMed ID: 10175783
[No Abstract] [Full Text] [Related]
6. Insurers' strategies for managing the use and cost of biopharmaceuticals.
Robinson JC
Health Aff (Millwood); 2006; 25(5):1205-17. PubMed ID: 16966716
[TBL] [Abstract][Full Text] [Related]
7. Getting serious about generics.
Sipkoff M
Manag Care; 2003 Jan; 12(1):36-9. PubMed ID: 12575509
[No Abstract] [Full Text] [Related]
8. When success sours: PBMs under scrutiny.
Carroll J
Manag Care; 2002 Sep; 11(9):20-6. PubMed ID: 12369344
[No Abstract] [Full Text] [Related]
9. Using clinical evidence to manage pharmacy benefits: experiences of six states.
Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
[TBL] [Abstract][Full Text] [Related]
10. Perspectives. Options vs. limits: drug cost strategies reconsidered.
Cunningham R
Faulkner Grays Med Health; 1997 Sep; 51(38):suppl 4. PubMed ID: 10173171
[No Abstract] [Full Text] [Related]
11. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry.
Dorfman HL; Reig LP
Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876
[No Abstract] [Full Text] [Related]
12. Targeting formulary pull-through strategies: the role of pharmaceutical manufacturers.
Navarro RP
Manag Care Interface; 1999 May; 12(5):84-6. PubMed ID: 10537482
[No Abstract] [Full Text] [Related]
13. The pills that ate your profits.
Meyer H
Hosp Health Netw; 1998 Feb; 72(3):18-22. PubMed ID: 9483145
[TBL] [Abstract][Full Text] [Related]
14. Dangerous spin doctors: seven steps to protect yourself from deception in medical research.
Hyman M
Explore (NY); 2011; 7(2):63-5. PubMed ID: 21397865
[No Abstract] [Full Text] [Related]
15. Pharmaceuticals & psychotropic drugs.
Health Aff (Millwood); 2009; 28(3):723. PubMed ID: 19414880
[No Abstract] [Full Text] [Related]
16. Kaiser Permanente's prescription drug benefit.
Levine S; Campen D; Millares M; Barrueta A
Health Aff (Millwood); 2000; 19(2):185-90. PubMed ID: 10718032
[No Abstract] [Full Text] [Related]
17. Formularies tighten and physicians adapt.
Lawrence J
Manag Care; 1998 Mar; 7(3):23-6, 29-30. PubMed ID: 10177957
[No Abstract] [Full Text] [Related]
18. What you need to know about Medicare Part D.
Consum Rep; 2006 Feb; 71(2):34-6. PubMed ID: 16509047
[No Abstract] [Full Text] [Related]
19. HMOs try formularies in effort to curb prescription costs.
Feldman A
Contract Healthc; 1988 Jul; ():33-5. PubMed ID: 10290628
[No Abstract] [Full Text] [Related]
20. MMA formulary design requires health plans to control costs.
Sipkoff M
Manag Care; 2005 Jun; 14(6):18, 20. PubMed ID: 16044883
[No Abstract] [Full Text] [Related]
[Next] [New Search]
